Tagged with Pharm

Pharma Legal Handbook 123. Are biosimilar medicines considered the same as generic medicines in your country? A biosimilar is not a generic biologic product since it is not identical to its reference product; its authorization does not constitute evidence of pharmaceutical equivalence, bioequivalence or clinical equivalence.[1] A biosimilar is a subsequent entry version…

Switzerland Clinigen is in the midst of a major transformation, repositioning itself as a pure services partner focused on bridging patient access to critical medicines worldwide. Its recent acquisition of SSI Strategy underscores this shift, combining SSI’s strategic depth, established U.S. and European footprint, and innovative partnership models with Clinigen’s global…

Europe Europe has a plasma problem. The continent is over-reliant on the US for plasma – donated, purified human blood liquid – which is a key component in several lifesaving drugs for immunity, bleeding, critical care, and rare disorders.   The Donor Dilemma One explanation for these shortages is the lack…

USA The latest stories from healthcare and the life sciences in the US. RFK Jr shares his 128 recommendations for addressing childhood chronic disease; Suspension of Capsida’s gene therapy clinical trial after patient death; Courts half another attempt to challenge the IRA’s negation program; Takeda scoops up former Lilly exec to…

China The top 20 Chinese pharma companies ranked by 2023 sales, according to the Citelie Scrip Asia 100. CSPC, Fosun, and Shanghai Pharma top the chart, with a host of other less well-known firms now also generating over a billion dollars in annual sales.   Made with Visme Infographic Maker

Switzerland As Medinova marks 80 years since its founding in Zurich, General Manager Olga Lamua Olivar is charting the path forward for the boutique specialty pharma player. With a career spanning multiple countries and disciplines, she brings the breadth of experience needed to guide Medinova through its next transformation. Her strategy…

Polepharma Fabien Riolet leads Polepharma, France’s leading pharmaceutical manufacturing network, driving industrial sovereignty and innovation across 460 member companies. Under his leadership, it has evolved into a strategic hub for manufacturing excellence, digital transformation, and sustainability, while positioning France for next-generation biopharma competitiveness. Our mission is clear: to preserve and strengthen…

Switzerland Fabien Stutz, Co-Founder and CEO of Pharmabotix, leads a new wave of pharma-tech entrepreneurs combining engineering expertise with cutting-edge automation. He has helped grow the Swiss-based company into a globally recognised firm, delivering bespoke systems to major clients across Europe and North America, while retaining the agility of a boutique…

Brazil As Latin America’s largest pharma market, worth USD 62 billion in 2024, Brazil is retooling its industry to meet new demands. Driven by changing demographics, chronic disease burdens, and the growing expectations of a more affluent middle class, the Brazilian government is prioritising local production in key therapeutic niches while…

Switzerland Dr. Roch Ogier, CEO of OM Pharma, brings a strong background spanning clinical medicine, neuroscience research, and leadership roles at Sanofi-Aventis, Vifor Pharma, and Novartis. Over the past eighteen months, he has driven solid growth and positioned the company as a leader in bacterial lysates, innovative therapies derived from selected…

Denmark Michael Kocher, Chief Executive Officer of Xellia, brings over 15 years of pharmaceutical industry experience to his leadership role at the Danish API manufacturer. Under his leadership since October 2023, the company has undertaken a comprehensive strategic realignment, divesting its US operations while refocusing on its core competencies in fermentation-based…

USA Michael Hogue, CEO of the American Pharmacists Association (APhA), shares his vision for the future of the pharmacy profession and its evolving role in healthcare. He discusses the strategic priorities for pharmacists in the coming years, emphasizing the need to reshape public perception, expand the role of pharmacists in disease…